A method and apparatus for treatment of cancer is provided. The method can include systemic administration of selective A3 adenosine receptor (A3AR) agonists like CI-IB-MECA (CF 101), LI-529, cordycepin or similar drugs in combination with application of pulsed Electric Field Stimulation (EFS) to the treatment area. A3AR agonists may be delivered in blend with allosteric enhancers of A3AR agonists potency like LUF6000 or other similar drugs. EFS is provided in three or more directions, which significantly increases expression of A3ARs on the cellular membranes and allows achieving a downstream apoptotic signal several-fold stronger than the signal created by an agonist alone. The apparatus may be dedicated to one patient usage over long period of time—hours and days continuously or intermittently.